1 Qian ZM, Shen X.Brain iron transport and neuridegeneration [J]. TrendMol.Med, 2001, 7:103-8
2 Jankovic, Joseph.Levodopa strengths and weaknesses[J]. Neurology, 2002;58:S19
3 Sorbera LA, Martin L, Etilevodopa.Antiparkinsonian dopamine precursor[J]. Drugs Future, 2001;26:219
4 Jenner P, Olanow CW.Oxidative stress and the pathogensis of Parkinson's disease[J]. Neurology, 1996;47:161
5 Jenner P.Pharmacology of dopamine agonists in the treatment of Parkinson's disease[J]. Neurology, 2002;58:S1
6 Contin M, Riva R, Albani F.Pharmacokinetic optimization of dopamine receptor agonist therapy for Parkinson's disease[J].cnS Drugs, 2000;14:439
7 Olanow CW.The role of dopamine agonists in the treatment of early Parkinson's disease[J]. Neurology, 2002;58:33
8 Hubble JP.Long-term studies of dopamine agonists[J]. Neurol-ogy, 2002;58:S42
9 Olanow CW, Schapira AH.Continuous dopaminergic stimulation in the early treatment of PD[J]. Treads Neurosci, 2000;23: 117
10 Schapira AH.Neuroprotection and dopamine agonists[J]. Neu-rology, 2002;58:S9
11 Yu P.Brasofensine Neurosearch[J]. Curr Opin Invest Drugs, 2000;1:504
12 HansardMJ, Smith LA.The antiparkinsonian ability of bupro-pion in MPTP-treated common marmosets[J]. Br J Pharmacol, 1998;125:S66
13 Negrotti A, Bizzarri G, Calzetti S.Long-term persistence of symptomatic eggect of selegiline in Parkinson's disease.A two-months placebo-controlled withdrawal stusy [J]. J Neural Transm, 2001;108:215
14 Rabey JM, Sagi I, HubermanM, Melamed E, KorczynA, Gi-ladi N, et al.Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease:a double-blind study as adjunctive therapy to levodopa [J]. Clin Neuropharmacol, 2000;23:324
15 Dingemanse J.Issue important for rational COMT inhibition [J]. Neurology, 2000;55:S24
16 张城.抗帕金森病新药硫酸盐[J]. 国外医学药学分册,2000;27:52
17 Schwarzschild MA, Chen JF, Ascherio A.Caffeinated clues and the promise of adenosine A2a antagonists in PD[J]. Neu-rology, 2002;58:1154-60
18 Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y.Actions of adenosine A2a receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by re-serpine or MPTP[J]. Psychopharmacology, 1999;147:90
19 Kanda T, Jackson MJ, Smith L, Pearce RK, Nakamura J, Kase H, et al.Combined use of the adenosine A2a antagonist KW-5002 with L-DOPA or with selective D 1 or D 2 dopamine ag-onists increases antiparkinsonian activity but not Dyskinesia in MPTP-treated monkeys[J]. Exp Neurol, 2000;162:321
20 Mogi M, Togari T.Brain derived growth factor and nerve growth factor concentration are decreased in the substantia nigra in Parkinson's disease[J]. Neurosci Lett, 1999;270:45
21 ChanhanNB, Siegel GJ, Lee JM.Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain[J]. J Chem Neuroanat, 2001;21: 277
22 Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, et al.Neuroprotective agents for clinical trials in Parkinson' disease;a systematic assessment[J]. Neurology, 2003;60:1234-40
23 Jankovic J.New and emerging therapies for Parkinson's disease [J]. Arch Neurol, 1999;56:785-90
24 Haller MF, Saltzman WM.Nerve growth factor delivery system [J]. J Control Release, 1998;53:1
25 Stocchi F, Olanow CW.Neuroprotection in Parkinson's dis-ease:Clinical trials[J]. AnnNeurol, 2003;53:S87-99
26 Delanty N, Dichter MA.Antioxidant therapy in neurologic dis-ease[J]. Arch Neurol, 2000;68:685-90 |
